---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-035655"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:28:21.120238+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Axsome Therapeutics Announces AXS-12 Meets Primary Endpoint in Phase 3 SYMPHONY Trial for Narcolepsy

## Summary
- AXS-12 reduced weekly cataplexy attacks by 83% vs 66% for placebo (p=0.018) at Week 5.
- Cataplexy remission achieved by 33% of AXS-12 patients vs 9.5% placebo (p=0.008).
- Excessive daytime sleepiness severity reduced (CGI-S p=0.027) and cognitive function improved (p=0.004).
- Concurrent EDS and cataplexy response in 57% of AXS-12 patients vs 33% placebo (p=0.029).

## SEC filing metadata
- accession: 0000950170-24-035655
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017024035655/0000950170-24-035655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017024035655/axsm-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-035655
- JSON: https://secwatch.observer/filing/0000950170-24-035655.json
- Plain text: https://secwatch.observer/filing/0000950170-24-035655.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.